Sigyn Therapeutics has released a note detailing the potential of its CardioDialysis device to transform cardiovascular disease treatment through blood purification technology. The announcement comes as cardiovascular disease remains the leading cause of death in the United States for more than a century, with current drug therapies showing limited effectiveness against the multiple circulating factors that fuel the condition.
The company's analysis reveals that multi-target blood purification devices like Lipoprotein Apheresis can reduce major adverse cardiovascular events by 75-95%, according to the American Heart Association. This contrasts sharply with statin drugs like Lipitor and Crestor, which achieve average reductions of only 25%. CardioDialysis aims to build upon this approach by addressing a wider range of cardiovascular disease targets while leveraging existing global dialysis infrastructure.
Unlike Lipoprotein Apheresis, which requires specialized apheresis centers, CardioDialysis can be deployed on standard dialysis machines already present in hospitals and clinics worldwide. This represents a significant strategic advantage, as there are more than 7,500 dialysis clinics in the United States compared to fewer than 60 apheresis center locations. Globally, approximately 50,000 dialysis clinics exist versus less than 800 apheresis centers.
The device's potential impact is particularly significant for end-stage renal disease patients, who represent a population of more than four million individuals worldwide receiving approximately 640 million dialysis treatments annually. Cardiovascular disease accounts for approximately 67% of ESRD patient deaths, with drug therapies showing little benefit in improving survival or reducing cardiovascular events in this group. CardioDialysis could be administered during regularly scheduled dialysis treatments, addressing what the company describes as a significant unmet need in global health.
Beyond patient benefits, the technology could substantially impact dialysis industry revenues. In the United States alone, extending the lives of approximately 550,000 ESRD patients on dialysis by just one month would boost top-line industry revenues by approximately $2.8 billion. The global market for Lipoprotein Apheresis was estimated at $300 million in 2024 and is projected to reach $650 million by 2033, based on treatment of approximately 5,500 individuals worldwide. This number represents just 1% of the U.S. dialysis patient population and slightly more than one-tenth of one percent of global ESRD patients on dialysis.
In vitro studies have demonstrated CardioDialysis's ability to address not only LDL-cholesterol and Lipoprotein(a) but also a broad spectrum of inflammatory factors implicated in cardiovascular disease progression. The company's clinical plan focuses initially on treating cardiovascular disease in ESRD patients, positioning the technology as more than a niche market opportunity given the vast majority of these patients suffer from cardiovascular disease and current treatments provide limited benefit.
For more information about Sigyn Therapeutics, visit https://www.SigynTherapeutics.com. Additional details about the original release can be found at https://www.newmediawire.com.
